A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region
Authors
Keywords
-
Journal
mBio
Volume 11, Issue 2, Pages -
Publisher
American Society for Microbiology
Online
2020-03-24
DOI
10.1128/mbio.00186-20
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene
- (2020) Yingyun Cai et al. mBio
- Nigeria's unending war with Lassa fever
- (2019) Paul Adepoju LANCET
- Ribavirin for the Treatment of Lassa Fever: A Systematic Review and Meta-Analysis
- (2019) Kirsten Alexandra Eberhardt et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- ICTV Virus Taxonomy Profile: Arenaviridae
- (2019) Sheli R. Radoshitzky et al. JOURNAL OF GENERAL VIROLOGY
- A review of Lassa fever vaccine candidates
- (2019) Kolawole Salami et al. Current Opinion in Virology
- A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
- (2019) Maria S. Salvato et al. Pathogens
- Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot
- (2019) Mathieu Mateo et al. Science Translational Medicine
- Mortality Among Confirmed Lassa Fever Cases During the 2015–2016 Outbreak in Nigeria
- (2018) Maryam Ibrahim Buba et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins
- (2018) Xavier Carnec et al. JOURNAL OF VIROLOGY
- Lassa fever and global health security
- (2018) The Lancet Infectious Diseases LANCET INFECTIOUS DISEASES
- Nigeria hit by unprecedented Lassa fever outbreak
- (2018) Leslie Roberts SCIENCE
- Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus)
- (2018) David X Liu et al. JOURNAL OF INFECTIOUS DISEASES
- Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018
- (2018) Katherine J. Siddle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays
- (2018) Yíngyún Caì et al. Viruses-Basel
- Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
- (2018) Tiago Abreu-Mota et al. Nature Communications
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
- (2017) Chad E Mire et al. NATURE MEDICINE
- Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein
- (2017) Benson Y.H. Cheng et al. VIROLOGY
- An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection
- (2017) Joseph W. Golden et al. Scientific Reports
- DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs
- (2017) Kathleen A. Cashman et al. Human Vaccines & Immunotherapeutics
- Understanding the cryptic nature of Lassa fever in West Africa
- (2017) Rory Gibb et al. Pathogens and Global Health
- Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies
- (2016) Robert W. Cross et al. ANTIVIRAL RESEARCH
- The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses
- (2016) Masaharu Iwasaki et al. JOURNAL OF VIROLOGY
- Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
- (2016) James E. Robinson et al. Nature Communications
- Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization
- (2015) Benson Yee Hin Cheng et al. JOURNAL OF VIROLOGY
- General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines
- (2015) Masaharu Iwasaki et al. JOURNAL OF VIROLOGY
- Molecular Mechanism for LAMP1 Recognition by Lassa Virus
- (2015) Hadas Cohen-Dvashi et al. JOURNAL OF VIROLOGY
- The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
- (2015) Angela Huttner et al. LANCET INFECTIOUS DISEASES
- International External Quality Assessment Study for Molecular Detection of Lassa Virus
- (2015) Sergejs Nikisins et al. PLoS Neglected Tropical Diseases
- A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses
- (2015) David Safronetz et al. PLoS Neglected Tropical Diseases
- The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset
- (2015) David Safronetz et al. Scientific Reports
- Lassa virus entry requires a trigger-induced receptor switch
- (2014) L. T. Jae et al. SCIENCE
- Mice Lacking Functional STAT1 Are Highly Susceptible to Lethal Infection with Lassa Virus
- (2013) N. E. Yun et al. JOURNAL OF VIROLOGY
- An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity
- (2013) Juan C Zapata et al. Virology Journal
- Vaccines for viral hemorrhagic fevers—progress and shortcomings
- (2013) Darryl Falzarano et al. Current Opinion in Virology
- Arenavirus Nucleoproteins Prevent Activation of Nuclear Factor Kappa B
- (2012) W. W. S. I. Rodrigo et al. JOURNAL OF VIROLOGY
- Reverse Genetics Recovery of Lujo Virus and Role of Virus RNA Secondary Structures in Efficient Virus Growth
- (2012) E. Bergeron et al. JOURNAL OF VIROLOGY
- Immune Responses and Lassa Virus Infection
- (2012) Marion Russier et al. Viruses-Basel
- The C-Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of the Type I Interferon Response
- (2011) E. Ortiz-Riano et al. JOURNAL OF VIROLOGY
- Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression
- (2011) K. M. Hastie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever
- (2010) Daniel G. Bausch et al. CLINICAL INFECTIOUS DISEASES
- Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs
- (2010) Xiaohong Jiang et al. VACCINE
- Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys
- (2009) S. Baize et al. JOURNAL OF VIROLOGY
- Risk Maps of Lassa Fever in West Africa
- (2009) Elisabeth Fichet-Calvet et al. PLoS Neglected Tropical Diseases
- Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates
- (2008) Igor S. Lukashevich et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now